Patients' response to therapy with rituximab and alemtuzumab, by site (n = 48)
| Disease (n) . | PB lymphocytosis,* no. (%) . | BM lymphocytosis,* no. (%) . | Lymphadenopathy,† no. (%) . | Liver/spleen enlargement,† no. (%) . |
|---|---|---|---|---|
| CLL (32) | 26 of 29 (90) | 9 of 25 (36) | 21 of 30 (70) | 8 of 10 (80) |
| CLL/PLL (9) | 7 of 8 (90) | 2 of 8 (25) | 3 of 7 (43) | 1 of 3 (33) |
| PLL (1) | 1 of 1 (100) | 1 of 1 (100) | — | — |
| MCL (3) | — | 2 of 2 (100) | 0 of 2 | 1 of 1 (100) |
| Richter transformation (2) | 1 of 2 (50) | 0 of 2 | 0 of 2 | 0 of 1 |
| Total | 36 of 40 (90) | 14 of 38 (37) | 24 of 41 (59) | 10 of 15 (67) |
| Disease (n) . | PB lymphocytosis,* no. (%) . | BM lymphocytosis,* no. (%) . | Lymphadenopathy,† no. (%) . | Liver/spleen enlargement,† no. (%) . |
|---|---|---|---|---|
| CLL (32) | 26 of 29 (90) | 9 of 25 (36) | 21 of 30 (70) | 8 of 10 (80) |
| CLL/PLL (9) | 7 of 8 (90) | 2 of 8 (25) | 3 of 7 (43) | 1 of 3 (33) |
| PLL (1) | 1 of 1 (100) | 1 of 1 (100) | — | — |
| MCL (3) | — | 2 of 2 (100) | 0 of 2 | 1 of 1 (100) |
| Richter transformation (2) | 1 of 2 (50) | 0 of 2 | 0 of 2 | 0 of 1 |
| Total | 36 of 40 (90) | 14 of 38 (37) | 24 of 41 (59) | 10 of 15 (67) |